Contributors
Patrizia Bacchini(Villa Torri Hospital), Raf Sciot(KU Leuven), Michael J. Klein(Hospital for Special Surgery), Julie C. Fanburg–Smith(University of Virginia Health System), G. Petur Nielsen(Harvard University), Angelo Paolo Dei Tos(University of Padua), Andrew E. Rosenberg(University of Miami), S. Fiona Bonar(North Sydney Orthopaedic and Sports Medicine Centre), Andrea T. Deyrup(Emory University), Edward F. McCarthy(Johns Hopkins University), Andrew Horvai(University of California, Los Angeles), Andrew L. Folpe(Mayo Clinic in Arizona), R. Lor Randall(University of California Davis Medical Center), Carrie Y. Inwards(Mayo Clinic), Franco Bertoni(University of Bologna), Leonard B. Kahn(Albert Einstein College of Medicine), John X. OʼConnell(University of British Columbia), Brian P. Rubin(Cleveland Clinic), Louis Guillou(Centre Hospitalier Universitaire Vaudois), Yasuaki Nakashima(University of Fukui)
Cited by 0
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k